Multi-layer Flow-modulating Stents for Thoraco-abdominal and Peri-renal XXXX : The UK Pilot Study.

@entity1 @entity449 @entity887 @entity439 @entity397 @entity655
OBJECTIVE: There remains a population of @entity1 with @entity449 that cannot be treated by conventional endovascular means. @entity655 ( @entity655 ) are a novel approach for the treatment of @entity449 ; this study reports outcomes of a UK pilot study of first-generation @entity655 in thoraco-abdominal (TAAA) and perirenal @entity439 (PAA) in @entity1 who were also unfit for open surgery. METHODS: @entity1 with TAAA and PAA unfit for open surgery and with no conventional options for endovascular repair were recruited. Follow-up included CTA at 1, 3, 6, and 12 months, then annually. Outcome measures included 30 day mortality, growth-free survival, branch vessel patency, complications, re-intervention, and maximal aortic diameter. RESULTS: @entity655 were implanted in 14 @entity1 (6 PAA, 8 TAAA) between October 2011 and March 2014 with one (7%) 30 day death and 11 (79%) surviving to 12 months. The median @entity439 growth was 9  mm in the first 12 months following implantation. On mean follow-up of 22.8 months, seven (50%) @entity1 had died including one confirmed @entity397 . AAA diameter remained stable in only two of the surviving @entity1 . Fifty of 51 covered aortic branches remained patent with no @entity887 or symptoms of ischaemia in any @entity1 . @entity655 dislocation occurred in four @entity1 , leading to re-intervention in two. A total of six re-interventions were performed in five @entity1 (35%) with one post-re-intervention death. CONCLUSION: These first-generation @entity655 were unstable and dislocated frequently. It is uncertain whether @entity655 implantation influenced the natural history of these @entity439 as none decreased in size, but two remain stable after a mean of 22.8 months. Although side branch patency was maintained, our results do not support the continued use of these first-generation devices. Further development is needed if this technology is to have a role in treatment of @entity449 .
